INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
Big Pharma's feeding frenzy carries on apace: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy

Big Pharma's feeding frenzy carries on apace: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy

Who is developing drugs for anti-microbial resistance (AMR) and Sepsis?

Hedley Rees's avatar
Hedley Rees
Dec 19, 2024
โˆ™ Paid
16

Share this post

INSIDE PHARMA
INSIDE PHARMA
Big Pharma's feeding frenzy carries on apace: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy
10
5
Share

Something I picked up on this morningโ€ฆfor critical thinkers

This is a big pharma marketing social media post:

๐Ÿ’‰ ๐“๐ก๐ž ๐ฅ๐š๐ง๐๐ฌ๐œ๐š๐ฉ๐ž ๐จ๐Ÿ ๐œ๐š๐ง๐œ๐ž๐ซ ๐ข๐ฆ๐ฆ๐ฎ๐ง๐จ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ฒ: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy.

๐Ÿ’‰ The first PD-1/PD-L1 inhibitors were approved just 10 years ago (Keytruda and Opdivo).

๐Ÿ’‰ Itโ€™s estimated that more than 700,000 ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐ ๐ฅ๐จ๐›๐š๐ฅ๐ฅ๐ฒ have been treated with PD-1/PD-L1 inhibitors since their introduction.

๐Ÿ’‰ The global market for PD-1/PD-L1 inhibitors is predicted to reach $110 ๐›๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐›๐ฒ 2031.

๐Ÿ’‰ Currently, there are 9 FDA-approved PD-1/PD-L1 inhibitors:

โš† Keytruda (pembrolizumab) โ€“ Merck
โš† Opdivo (nivolumab) โ€“ Bristol Myers Squibb
โš† Tecentriq (atezolizumab) โ€“ Roche/Genentech
โš† Imfinzi (durvalumab) โ€“ AstraZeneca
โš† Bavencio (avelumab) โ€“ Merck Group/Pfizer
โš† Libtayo (cemiplimab) โ€“ Regeneron/Sanofi
โš† Jemperli (dostarlimab) โ€“ GSK
โš† Zynyz (retifanlimab) โ€“ Incyte
โš† Loqtorzi (toripalimab) โ€“ Coherus BioSciences/Shanghai Junshiโ€ฆ

This post is for paid subscribers

Already a paid subscriber? Sign in
ยฉ 2025 Hedley Rees
Privacy โˆ™ Terms โˆ™ Collection notice
Start writingGet the app
Substack is the home for great culture

Share